Covid Cover-Up Excuses: When Following Policy Is Wrong

• The ICH has introduced a new standardized framework for clinical trial protocols consisting of a harmonized guideline, a protocol template, and a technical specification for electronic exchange. • These documents apply to all phases and therapeutic areas of interventional clinical trials, including pharmaceuticals, biologics, vaccines, and cell or gene therapy products.

• The FDA has accepted Roche's application to use the combination of Lunsumio and Polivy for patient treatment. • This regulatory milestone is part of Roche's effort to expand the indications and clinical utility of these existing in-market products.

• The US Administration is restructuring the systems supporting PEPFAR and global health security, shifting its engagement strategy toward regulatory influence over long-term public health partnerships. • Concerns are rising that increased political oversight and the deconstruction of international collaborations may undermine the NIH's scientific infrastructure and its history of HIV research and vaccine development.

• U.S. Health Secretary Robert F. Kennedy Jr. announced over $700 million in new funding opportunities on Wednesday to address mental illness, addiction, and homelessness. • The financial package includes $238.6 million for the 988 Suicide and Crisis Lifeline and $223.1 million for Certified Community Behavioral Health Clinics.

• Pfizer expanded its obesity pipeline through a $150 million deal for YaoPharma’s oral GLP-1 agonist and a separate $150 million investment in GLP-1 and amylin drug candidates. • Sanofi acquired Blueprint Medicines for $9.5 billion to secure oncology and rare disease assets, including the approved drug Ayvakit.

• The FDA has granted a new indication for the drug Tzield, expanding its use to patients who have already progressed to Stage 3 type 1 diabetes. • This latest approval aims to preserve residual beta cell function, building on previous expansions in April 2026 that extended the drug's use to children as young as one year old.

• U.S. Trade Representative Jamieson Greer announced on Thursday that the U.S. has launched a trade investigation into Germany's pharmaceutical pricing policies. • The probe follows an April proposal by the German Ministry of Health to overhaul its statutory healthcare system to close a 20 billion euro ($23 billion) funding gap.

• At the Reuters Pharma USA 2026 event, industry experts discussed the shift toward "optichannel" engagement to better influence physician prescribing habits. • AstraZeneca’s IO Women’s Cancer Lead, Dicla Veliz Salce, highlighted that strong clinical trial data alone is often insufficient to change medical behavior.

• UCLA researchers have developed an experimental drug called AD-NP1, designed to block the protein ENPP1 to prevent heart failure and promote heart tissue healing after a heart attack. • New lab experiments indicate the drug may also be effective for kidney repair, as biopsies from patients with chronic kidney disease show elevated levels of the same ENPP1 protein.

• The Democratic Republic of Congo reported that confirmed Ebola cases have risen to 896, with 232 deaths recorded as of late Thursday. • Government data indicates a significant increase in infections, highlighting the severity of the current health crisis.

• A new study reveals that Texas's abortion ban has led to a 2.52 percentage-point increase in maternal mental health issues, with the impact more than doubling for mothers using Medicaid or CHIP. • Data presented by Dr. Julie Kanter at the European Hematology Association 2026 Congress shows that current clinical trial eligibility for sickle cell disease (SCD) therapies excludes 90% of adults living with the condition.